Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;11(4):218.
doi: 10.1186/cc5937.

Clinical review: Patency of the circuit in continuous renal replacement therapy

Michael Joannidis  1 , Heleen M Oudemans-van Straaten
Affiliations
Review

Clinical review: Patency of the circuit in continuous renal replacement therapy

Michael Joannidis et al. Crit Care. 2007.

Abstract

Premature circuit clotting is a major problem in daily practice of continuous renal replacement therapy (CRRT), increasing blood loss, workload, and costs. Early clotting is related to bioincompatibility, critical illness, vascular access, CRRT circuit, and modality. This review discusses non-anticoagulant and anticoagulant measures to prevent circuit failure. These measures include optimization of the catheter (inner diameter, pattern of flow, and position), the settings of CRRT (partial predilution and individualized control of filtration fraction), and the training of nurses. In addition, anticoagulation is generally required. Systemic anticoagulation interferes with plasmatic coagulation, platelet activation, or both and should be kept at a low dose to mitigate bleeding complications. Regional anticoagulation with citrate emerges as the most promising method.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of contact activation by hemofilter membranes. ADP, adenosine diphosphate; C, complement factor; GP, glycoprotein; HMWK, high molecular weight kininogens; PAF, platelet activating factor released by polymorphonuclear cells; plt., platelets; RBC, red blood cells; TF, tissue factor expressed by adhering monocytes; TXA, thromboxane A2.
Figure 2
Figure 2
Features of vascular access contributing to extracorporeal blood flow. ICV, inferior caval vein; P, pressure; Q, blood flow; RA, right atrium.
See this image and copyright information in PMC

References

    1. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222. doi: 10.1186/cc4975. - DOI - PMC - PubMed
    1. Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int. 1999;55:1568–1574. doi: 10.1046/j.1523-1755.1999.00397.x. - DOI - PubMed
    1. Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M. Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med. 1997;23:38–43. doi: 10.1007/s001340050288. - DOI - PubMed
    1. Bouman CS, de Pont AC, Meijers JC, Bakhtiari K, Roem D, Zeerleder S, Wolbink G, Korevaar JC, Levi M, de Jonge E. The effects of continuous venovenous hemofiltration on coagulation activation. Crit Care. 2006;10:R150. doi: 10.1186/cc5080. - DOI - PMC - PubMed
    1. Baldwin I, Bellomo R, Koch B. Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med. 2004;30:2074–2079. doi: 10.1007/s00134-004-2440-0. - DOI - PubMed

MeSH terms